CareLit Fachartikel

Safety and tolerability of empagliflozin in patients with type 2 diabetes

S Kohler, A Salsali, S Hantel, G Kim, HJ Woerle, UC Broedl · Diabetologie und Stoffwechsel · 2016 · Heft 04

Dokument
1145902
CareLit-ID
Jahr
2016
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig

Bibliografische Angaben

Zeitschrift
Diabetologie und Stoffwechsel
Autor:innen
S Kohler, A Salsali, S Hantel, G Kim, HJ Woerle, UC Broedl
Ausgabe
Heft 04 / 2016
Seiten
–
Erschienen: 2016-04-19 00:00:00
ISSN
1861-9002
DOI
10.1055/s-0036-1580888

Zusammenfassung

Aim: To assess the safety and tolerability of empagliflozin using data pooled from Phase I, II and III trials in patients with type 2 diabetes (T2DM). Methods: Pooled safety data were analyzed from patients with T2DM who received placebo (n = 3695), empagliflozin 10 mg (n = 3806) or empagliflozin 25 mg (n = 4782) in Phase I, II and III trials (including extensions). Adverse events (AEs) were assessed descriptively in patients who took ≥1 dose of study drug. Incidences are rates per 100 patient-years. Results: Total exposure was 3254, 3840 and 5649 patient-years in the placebo, empagliflozin 10 mg and 25 mg group…

Schlagworte

Empagliflozin Respectively Placebo Patients Events Pooled Groups Consistent Based Safety Phase Trials Diabetologie und Stoffwechsel